STOP2 – Standardized Treatment of Pulmonary Exacerbations
Full IRB Study Title:
Standardized Treatment of Pulmonary Exacerbation II (STOP2) Protocol No: STOP2-IP-15
IRB Study ID: 966544-18
For complete study information, view the study on clinicaltrials.gov
Study Sponsor:
CFFT Therapeutics Development Network Coordinating Center (TDNCC)
Who May Qualify:
Patients with Cystic Fibrosis ≥ 18 years of age planned to initiate intravenous (IV) antibiotics for a pulmonary exacerbation
Who Does NOT Qualify:
Patients who have been treated with IV antibiotics within 6 weeks prior to Visit 1
Lead Investigator
Gregory Omlor, MD, FAAP
Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine